Ed Lascelles
Partner @ AlbionVC
London, United Kingdom
Ed Lascelles is a Series A investor at AlbionVC in London focused on SaaS and FinTech. Ed has been investing with Albion since 2004 and oversees many of the technology investments in the VCTs as well as the physical sciences and engineering investments for the UCL Technology Fund. Prior to Albion, Ed worked at ING Barings advising UK public companies on M&A, IPOs and fundraisings in the tech, healthcare and financial servicessector. Ed graduated from UCL with a 1st class degree in Philosophy.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Ed Lascelles invests in
Stages Ed Lascelles invests in
Countries Ed Lascelles invests in
Investment Focus
Industry
- SaaS 2 (22%)
- FinTech 2 (22%)
- Email 1 (11%)
- Chatbot 1 (11%)
- Medical 1 (11%)
Stage
- Series A 3 (33%)
- Seed 1 (11%)
- Series B 1 (11%)
- Series C 1 (11%)
- Funding Round 1 (11%)
Country
- United Kingdom 5 (56%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
OpenDialog AI
|
OpenDialog is a conversational AI platform that facilitates the design, development, and deployment of more intelligent human-to-machine conversations. The company empowers enterprises to craft customized AI chatbots and digital assistants, providing precise control for automation and compliance. These solutions gather millions of data pointsdaily, contributing to ongoing improvements and enhancements. | $8M / Series A / Jan 24, 2024 | |
5Mins
|
5Mins s a gamified learning platform designed to help employees improve their skills .It curates short-form video content from leading creators around the world and makes it available to teams and businesses via adaptive and gamified learning engine. | $5.7M / Seed / Nov 07, 2022 | |
Runa
|
Runa is rewriting the rules of payouts and building what comes next. Weʼre the global fintech powering seamless value exchange, giving businesses the tools to grow faster, reach further, and turn every payout into something more. With a single API, Runa unlocks instant access to over 5 billion consumers in 190 countries. Cards, wallets, bankaccounts, digital rewards—you name the funds flow fast, friction-free, and fully embedded into any experience. No borders. No friction. Just possibilities unlocked. Based in London and New York with a global team at the helm, Runa is backed by investors like Element Ventures, CommerzVentures, Clocktower Ventures, Volution Capital, 13Books Capital, and SAP.Letʼs go further—runa.io | $10.2M / Series A / Nov 25, 2020 | |
Credit Kudos
|
Credit Kudos is a credit bureau that uses financial behaviour to measure creditworthiness. It utilizes consumer transaction data to build highly accurate and transparent credit score-cards and affordability metrics. | $6.3M / Series A / Apr 15, 2020 | |
Egress Software
|
Egress is a software company that specializes in human layer security designed to prevent accidental and intentional data breaches. Its mission is to eliminate the greatest risk to every business the insider threat. To achieve this Egress has built the world’s only Human Layer Security platform that empowers your people to remain secure while beinghighly productive. | $40M / Series C / Dec 18, 2018 | |
Xceleron
|
Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration.Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered humanmicrodose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials.Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development. | Jan 20, 2010 | |
|
Xceleron
|
Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration.Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered humanmicrodose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials.Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development. | $2.5M / Series B | |
|
Xceleron
|
Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration.Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered humanmicrodose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials.Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development. | $2.5M | |
|
Xceleron
|
Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration.Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered humanmicrodose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials.Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development. | $2.4M |
Co-Investors
About AlbionVC
AlbionVC supports visionary founders and technologies with long-term capital and scale-up know-how. Founded in 1996, it was amongst the first to back leading global success stories such as Booking.com, Egress, Quantexa and Oviva. With £1bn in AUM and over 100 exits successfully realised, it funds venture breakthroughs that drive real outcomes forfounders, investors and society. AlbionVC is the technology investment arm of Albion Capital Group, which is authorised and regulated by the Financial Conduct Authority. For more information please visit: https://albion.vc/
AlbionVC Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Chirkowski
Partner
|
|||
Christoph Ruedig
Partner
|
|||
|
Ed Lascelles
Partner
|
|||
Andrew Elder
Deputy Managing Partner
|
|||
Cat McDonald
Investment Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ed Lascelles invest in?
Ed Lascelles invests primarily in SaaS, FinTech and Email startups, most often at Series A and Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ed Lascelles last invest?
The most recent investment recorded for Ed Lascelles closed in Jan 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
